Items where Subject is "Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Molecular Targets (111207)"
|Up a level|
- Subjects classification (46785)
- Australian and New Zealand Standard Research Classification (46785)
Group by: Authors/Creators | Item Type
Number of items at this level: 35.
Jingjing, You, Cozzi, Paul, Fitzgerald , Anna, Walsh, Bradley, Russell, Pamela J., Willcox, Mark, et al. (2012) Prostate cancer biomarkers and the emerging proteomic techniques used in biomarker research. In Watanabe, Hiroto S. (Ed.) Horizons in Cancer Research : Volume 47. Nova Science Publishers Inc, New York, pp. 1-36.
Byron, Sara A., Gartside, Michael, Powell, Matthew A., Wellens, Candice L., Gao, Feng, Mutch, David G., et al. (2012) FGFR2 point mutations in 466 Endometrioid Endometrial Tumors : relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and Clinicopathological features. PLoS ONE, 7(2), e30801-e30801.
Byron, Sara A., Loch, David, & Pollock, Pamela M. (2012) Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. International Journal of Gynecological Cancer, 22(9), pp. 1517-1526.
Byron, Sara A., Loch, David C. , Wellens, Candice L., Wortmann, Andreas, Wu, Jiayi, Wang, John, et al. (2012) Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. BMC Molecular Cancer, 11(75).
Chopin, L. K., Seim, I., Walpole, C. M., & Herington, A. C. (2012) The Ghrelin axis : does it have an appetite for cancer progression? Endocrine Reviews, 33(6), pp. 849-891.
Dong, Ying, Batra, Jyotsna, Anand, Kamal, Bapat, Sharmila, & Clements, Judith A. (2014) Transforming the future of treatment for ovarian cancer. Clinical & Experimental Pharmacology, 4(3), p. 1000157.
Dutton-Regester, Ken & Hayward, Nicholas K. (2012) Whole genome and exome sequencing of melanoma. Advances in Pharmacology, 65, pp. 399-435.
Dutton-Regester, Ken, Irwin, Darryl, Hunt, Priscilla, Aoude, Lauren G., Tembe, Varsha, Pupo, Gulietta M., et al. (2012) A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Molecular Cancer Therapeutics, 11(4), pp. 888-897.
Fuchs, Adrian V., Tse, Brian W.C., Pearce, Amanda K., Yeh, Mei-Chun, Fletcher, Nicholas L., Huang, Steve S., et al. (2015) Evaluation of polymeric nanomedicines targeted to PSMA: Effect of ligand on targeting efficiency. Biomacromolecules, 16(10), pp. 3235-3247.
Hao, J, Chen, H, Madigan, M C, Cozzi, P J, Beretov, J, Xiao, W, et al. (2010) Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. British Journal of Cancer, 103(7), pp. 1008-1018.
Herington, A.C., Mertens-Walker, I., Lisle, J.E., Maharaj, M., & Stephenson, S.-A. (2014) Inhibiting Eph kinase activity may not be “Eph”ective for cancer treatment. Growth Factors, 32(6), pp. 207-213.
Krauthammer, Michael, Kong, Yong, Ha, Byung Hak, Evans, Perry, Bacchiocchi, Antonella, McCusker, James P, et al. (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics, 44(9), pp. 1006-1014.
Libério, Michelle S., Sadowski, Martin, Nelson, Colleen C., & Davis, Rohan A. (2014) Identification of eusynstyelamide B as a potent cell cycle inhibitor following the generation and screening of an ascidian-derived extract library using a real time cell analyzer. Marine Drugs, 12(10), pp. 5222-5239.
Lim, Yenkai, Sun, Charles Xiaohang, Tran, Peter, & Punyadeera, Chamindie (2016) Salivary epigenetic biomarkers in head and neck squamous cell carcinomas. Biomarkers in Medicine, 10(3), pp. 301-313.
Lisle, J.E., Mertens-Walker, I., Stephens, C.R., Stansfield, S.H., Clements, J.A., Herington, A.C., et al. (2015) Murine, but not human, ephrin-B2 can be efficiently cleaved by the serine protease kallikrein-4: Implications for xenograft models of human prostate cancer. Experimental Cell Research, 333(1), pp. 136-146.
Lisle, Jessica E., Mertens-Walker, Inga, Rutkowski, Raphael, Herington, Adrian C., & Stephenson, Sally-Anne (2013) Eph receptors and their ligands : promising molecular biomarkers and therapeutic targets in prostate cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1835(2), pp. 243-257.
Loch, David & Pollock, Pamela M. (2012) Lineage-specific biomarkers predict response to FGFR inhibition. Cancer Discovery, 2, pp. 1081-1083.
Maddaluno, Luigi, Verbrugge, Sue Ellen, Martinoli, Chiara, Matteoli, Gianluca, Chiavelli, Andrea, Zeng, Yiping, et al. (2009) The adhesion molecule L1 regulates transendothelial migration and trafficking of dendritic cells. Journal of Experimental Medicine, 206(3), pp. 623-635.
Mertens-Walker, Inga, Fernandini, Bruno C., Maharaj, Mohanan S.N., Rockstroh, Anja, Nelson, Colleen C., Herington, Adrian C., et al. (2015) The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of Integrin-β8 in prostate cancer cells. BMC Cancer, 15(164).
Mertens-Walker, Inga, Lisle, Jessica E., Nyberg, William A., Stephens, Carson R., Burke, Leslie, Rutkowski, Raphael, et al. (2015) EphB4 localises to the nucleus of prostate cancer cells. Experimental Cell Research, 333(1), pp. 105-115.
Moore, Nicole L., Buchanan, Grant, Harris, Jonathan M., Selth, Luke A., Bianco-Miotto, Tina, Hanson, Adrienne R., et al. (2012) An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocrine Related Cancer, 19(4), pp. 599-613.
Rutowski, Raphael, Mertens-Walker, Inga, Lisle, Jessica E, Herington, Adrian C., & Stephenson, Sally-Anne (2012) Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand. International Journal of Cancer, 131(5), E614-E624.
Seim, Inge, Jeffery, Penny L., Herington, Adrian C., & Chopin, Lisa K. (2015) Comparative analysis reveals loss of the appetite-regulating peptide hormone ghrelin in falcons. General and Comparative Endocrinology, 216, pp. 98-102.
Soekmadji, Carolina, Riches, James D., Russell, Pamela J., Ruelcke, Jayde E., McPherson, Stephen, Wang, Chenwei, et al. (2016) Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer. Oncotarget. (In Press)
Stephenson, Sally-Anne, Douglas, Evelyn L., Mertens-Walker, Inga, Lisle, Jessica E., Maharaj, Mohanan S.N., & Herington, Adrian C. (2015) Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4. Oncotarget, 6(10), pp. 7554-7569.
Vela, Ian & Chen, Yu (2015) Prostate cancer organoids: A potential new tool for testing drug sensitivity. Expert Review of Anticancer Therapy, 15(3), pp. 261-263.
You, Jingjing, Willcox, Mark, Fitzgerald, Anna, Schiller, Belinda, Cozzi, Paul J., Russell, Pamela J., et al. (2015) Absolute quantification of human tear lactoferrin using multiple reaction monitoring technique with stable-isotopic labeling. Analytical Biochemistry, 496, pp. 30-34.
Rhee, H., Heathcote, P., Wood, S., Greenslade, S., Russell, P., Nelson, C., et al. (2015) Clinical application of biomarkers in prostate cancer in men with metabolic syndrome project: Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in diagnosing localised prostate cancer. In 24th Malaysian Urological Conference (MUC 2015), 19 November 2015, Malaysia.
Rhee, Handoo, Vela, Ian, Gunter, Jennifer, Jovanovic, Lidija, Hollier, Brett, Williams, Elizabeth, et al. (2015) Clinical application of biomarkers in prostate cancer in men with metabolic syndrome project: Clinical evaluation of prognostic and metabolic benefits of Metformin in prostate cancer. In Urological Society of Australia and New Zealand 68th Annual Scientific Meeting, 11–14 April 2015, Adelaide, Australia.
Soekmadji, Carolina, Ruelcke, Jayde E., Wang, Chenwei, Riches, James D., McPherson, Stephen, Russell, Pamela, et al. (2015) Extracellular vesicles mediate paracrine signalling in androgen deprived prostate cancer. In 2nd Prostate Cancer World Congress, 17-21 August 2015, Cairns Convention Centre, Cairns, Qld.
Tevz, Gregor, Hossain, Akther, Bock, Nathalie, Jeet, Varinder, Bathgate, Ross A., Williams, Elizabeth D., et al. (2015) Impeding the adaptive response of prostate cancer to androgen targeted therapies with relaxin receptor antagonist. In 2nd Prostate Cancer World Congress, 17-21 August 2015, Cairns Convention Centre, Cairns, Qld.
Tse, B.W.C., Cowin, G.J., Soekmadji, C., Jovanovic, L., Vasireddy, R., Ling, M.T., et al. (2014) Enhancing MRI of prostate cancer using PSMA-targeting iron oxide magnetic nanoparticles. In 67th Annual Scientific Meeting of the Urological Society of Australia and New Zealand (USANZ 2014), 16–19 March 2014, Brisbane, Qld.
Tse, Brian W-C, Fuchs, Adrian V., Huang, Steve S., Heston, Warren DW, Yeh, Mei-Chun, Whittaker, Andrew K., et al. (2015) Multimodal hyperbranched polymers targeting prostate specific membrane antigen (PSMA) for imaging of prostate cancer. In 2nd Prostate Cancer World Congress, 17-21 August 2015, Cairns Convention Centre, Cairns, Qld.
Volpert, Marianna, Tse, Brian W.C., Stylianou, Nataly, Ratther, Ellca, McPherson, Stephen, Costa, Taylor, et al. (2015) Targeting neuropilin-1 to inhibit prostate cancer invasion and metastasis. In 2nd Prostate Cancer World Congress, 17-21 August 2015, Cairns Convention Centre, Cairns, Qld.
Williams, Elizabeth D. & Thompson, Erik W. (2015) How cancer doctors use personalized medicine to target variations unique to each tumour. Conversation.